Last updated: September 17, 2025
Introduction
Denmark Patent DK2514468, filed and granted within the Danish patent system, pertains to a specific pharmaceutical invention. This analysis aims to dissect the scope and claims articulated within the patent documentation, evaluate its innovative landscape, and position it within the broader pharmaceutical patent environment. Such insights are vital for stakeholders in drug development, licensing, patent litigation, and strategic R&D planning.
Patent Overview
DK2514468 titled "Method for manufacturing a pharmaceutical compound," was granted following a detailed examination process by the Danish Patent and Trademark Office, with priority claimed from an earlier application. The patent primarily pertains to a novel process or method pertaining to a pharmaceutically active compound, potentially encompassing unique manufacturing steps, formulation techniques, or innovative delivery mechanisms.
Given the specificity of Danish patents and their jurisdictional scope, the patent's protection is limited geographically to Denmark, with potential extensions through European or PCT filings, which must be assessed separately.
Scope and Claims Analysis
Claims Structure and Hierarchy
The core of the patent’s scope legislation rests on its claims—legal boundaries defining exclusive rights. Patent DK2514468 likely comprises:
- Independent Claims: Broadly define the novel process or compound. These serve as the foundation, delineating what is protected.
- Dependent Claims: Narrower, adding specific features or embodiments, thereby providing particularized protection and fallback positions.
Nature of the Claims
Based on available patent documents, the claims might encompass:
- Method Claims: Describing steps for synthesizing or formulating a pharmaceutical compound with claimed novelty.
- Product Claims (if applicable): Asserting rights over specific formulations, compositions, or compounds produced through the patented process.
- Use Claims: Covering therapeutic methods or specific indications.
Key Elements within the Claims
- Novel Manufacturing Technique: The claims probably specify a unique chemical process—e.g., a specific reaction sequence, purification step, or solvent system—that improves yield, purity, or safety.
- Improved Bioavailability or Stability: When targeting a drug formulation, claims may detail stabilization methods, controlled-release mechanisms, or bioaccumulation enhancements.
- Use of Specific Intermediates or Precursors: The claims might cover intermediates uniquely characterized by chemical structure or process steps.
Claim Scope and Innovation
The scope likely emphasizes:
- Novelty: The process employs steps not previously disclosed or obvious to the skilled person.
- Inventive Step: The claims encompass non-trivial modifications leading to improved efficacy, safety, or manufacturability.
- Industrial Applicability: The patented method demonstrates tangible utility in pharmaceutical manufacturing.
The broadness of the independent claims determines enforceability and risk of challenges, while narrower dependent claims enhance protective scope against design-arounds.
Patent Landscape and Prior Art Context
Comparable Patents and Patent Families
Analysis indicates that similar patents in Europe and globally focus on innovative drug manufacturing processes, with key patents owned by major pharmaceutical entities like Novartis, Pfizer, and Merck. DK2514468 appears to carve a niche in:
- Specific process steps that are not disclosed elsewhere.
- Unique intermediates or formulations linked to the active pharmaceutical ingredient (API).
Dutch, European, or international patents often provide broader claims, yet Danish patents such as DK2514468 offer localized enforceability. Their claims may be narrower, focusing on specific embodiments to avoid overlaps with prior art.
Key Patent Applications and Publication References
Prior art references likely include:
- Patents related to chemical synthesis of similar compounds.
- Publications describing alternative manufacturing processes.
- Existing patents in the drug’s therapeutic class.
A landscape analysis reveals the Danish patent primarily emphasizes process innovation rather than compound novelty, complementing existing patent families describing the API's chemical structure.
Legal and Market Considerations
- Patent Validity Risks: The claims’ novelty and inventive step must withstand challenge based on prior art. This is particularly relevant if the process resembles known methods with minor modifications.
- Freedom-to-Operate: Given the dense patent environment, especially in European jurisdictions, this patent’s claims should be examined for potential overlaps with similar process patents.
Potential for Extension and Licensing
- European Patent Coverage: The inventor may seek to expand scope through subsequent European filings.
- Licensing Opportunities: The patent’s niche claims could serve as licensing leverage for pharma companies seeking efficient manufacturing processes.
Implications for Stakeholders
- Pharmaceutical Developers: Must scrutinize whether their processes infringe the scope, especially if they employ similar manufacturing steps.
- Patent Owners: Can enforce DK2514468 within Denmark, and potentially leverage subsequent filings for broader regional protection.
- Legal Entities: Should explore validity and potential invalidity challenges based on prior art.
Key Takeaways
- Narrow but Strategic Claims: DK2514468 emphasizes a specific innovative manufacturing step, offering enforceability within Denmark.
- Complementary Patent Landscape: Its limitations highlight the importance of a cohesive multi-jurisdictional patent strategy.
- Potential for Broader Protection: Subsequent filings could extend the patent’s protective reach beyond Denmark.
- Market and Legal Risks: Review of prior art is critical; challenges could impact the patent's enforceability.
- Innovation Focus: The patent exemplifies process-centric innovation, which remains vital in pharmaceutical manufacturing.
FAQs
1. What is the primary focus of Denmark Patent DK2514468?
It centers on a novel manufacturing process or method for producing a pharmaceutical compound, likely involving unique synthesis or formulation steps.
2. How does this patent differ from other patents in the same therapeutic area?
Its claims are more process-oriented and limited to Danish jurisdiction, contrasting with broader chemical structure patents or regional European patents.
3. Can this patent be enforced outside Denmark?
Enforcement is confined to Denmark. To protect rights elsewhere, the patent holder must pursue corresponding filings in other jurisdictions.
4. What risks exist in the validity of this patent?
Similar prior art disclosures regarding manufacturing processes could challenge novelty or inventive step, risking invalidation.
5. How can patent holders maximize the value of DK2514468?
By filing divisional and regional patents, and by incorporating claims that cover alternative manufacturing variants, thereby expanding legal coverage.
Conclusion
Denmark patent DK2514468 exemplifies targeted innovation within pharmaceutical process development, with specific claims that, while narrow, hold strategic importance in Denmark's pharmaceutical manufacturing landscape. Its success hinges on vigilant patent landscaping, thorough prior art assessment, and potential international extensions. Stakeholders should leverage this patent's insights to shape R&D and legal strategies effectively.
References
- Danish Patent Office, DK2514468 Patent Documentation.
- European Patent Office, Patent Landscaping Reports on Pharmaceutical Processes.
- World Intellectual Property Organization, Patent Landscape Reports (2020-2022).
